Table 2.
Frequency of mentions and prevalence of signs/symptoms and life impacts in the selected publications
| Overall | Subpopulationsa | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (N = 100) | General (N = 48) | Diabetes (N = 11) | Anaemia (N = 7) | CKD 1–3 (N = 9) | CKD 4–5 (N = 14) | Dialysis (N = 26) | ||||||||
| Freq. | Prev. | Freq. | Prev. | Freq. | Prev. | Freq. | Prev. | Freq. | Prev. | Freq. | Prev. | Freq. | Prev. | |
| Signs/symptomsb | ||||||||||||||
| Pain/discomfort | 57 | 73 | 58 | 75 | 36 | NR | 71 | 68 | 44 | 60 | 57 | 100 | 73 | 75 |
| Tiredness/low energy/lethargy/fatigue | 42 | 100 | 31 | 100 | 27 | NR | 86 | 50 | 22 | 24 | 36 | 76 | 62 | 71 |
| Disturbed sleep/sleep-related problems | 28 | 94 | 33 | 94 | – | – | – | – | 11 | 55 | 29 | 66 | 38 | 80 |
| Itching/skin problems | 25 | 89 | 17 | 89 | 18 | NR | – | – | 22 | NR | 29 | 84 | 42 | 83 |
| Muscular pain/cramps | 18 | 89 | 17 | 89 | 18 | 44 | – | – | 11 | 55 | 7 | 83 | 31 | 69 |
| Appetite loss/anorexia | 18 | 67 | 15 | 67 | 9 | NR | – | – | – | – | 21 | 32 | 35 | 53 |
| Nausea | 18 | 59 | 8 | 38 | 18 | NR | – | – | – | – | 21 | 59 | 38 | 42 |
| Dyspnoea/shortness of breath | 17 | 80 | 12 | 67 | 9 | 36 | 14 | NR | – | – | 21 | 80 | 31 | 66 |
| Feeling unwell | 7 | 55 | 4 | NR | 27 | 52 | – | – | 11 | NR | 7 | NR | 8 | 36 |
| Dizziness | 7 | 50 | – | – | – | – | – | – | – | – | – | – | 27 | 50 |
| Life impactsb | ||||||||||||||
| Anxiety/depression | 49 | 83 | 56 | 39 | 27 | 83 | 14 | NR | 55 | 33 | 43 | 65 | 54 | 57 |
| Mental impact | 26 | 26 | 27 | 21 | 55 | 26 | 43 | NR | – | – | 7 | NR | 23 | NR |
| Mood change/irritability | 12 | 50 | 10 | 50 | 36 | NR | – | – | 11 | NR | 14 | NR | 8 | 24 |
| Physical functioning | 43 | 83 | 52 | 83 | 55 | NR | 86 | NR | 22 | 61 | 14 | NR | 35 | 14 |
| Emotional interference | 37 | 82 | 35 | 82 | 45 | NR | 43 | NR | – | – | 14 | NR | 54 | 45 |
| Social relationship interference | 34 | 60 | 31 | 89 | 64 | NR | 57 | 83 | 11 | 26 | 7 | NR | 38 | 28 |
| Cognitive impairment (memory, concentration, confusion) | 27 | 61 | 31 | 71 | 9 | 36 | – | – | 33 | 14 | 14 | NR | 35 | 52 |
| General health perception | 26 | 36 | 27 | 19 | 27 | NR | 57 | NR | 11 | NR | 7 | NR | 31 | 36 |
| ADL/daily/regular activities | 24 | 80 | 25 | 46 | – | – | 28 | 83 | 33 | 49 | 14 | 80 | 38 | 60 |
| Diet/food changes/related | 23 | 83 | 23 | 74 | 36 | 43 | – | – | – | – | 7 | 40 | 27 | 48 |
| Vitality | 23 | 60 | 19 | 24 | 36 | NR | 86 | 60 | 22 | NR | 14 | NR | 23 | NR |
| Mobility problems | 16 | 100 | 21 | 61 | 9 | NR | 14 | NR | 33 | 45 | 21 | 100 | 19 | 70 |
| Self-care issues | 10 | 88 | 8 | NR | 9 | NR | 28 | NR | 22 | 18 | 21 | 68 | 12 | 88 |
| Activity impairment | 9 | 89 | 6 | 89 | 18 | NR | 43 | 22 | 11 | 52 | 7 | 48 | 12 | 52 |
Freq. (frequency): values indicate the proportion (%) of publications in which each sign/symptom or life impact was mentioned (−, not mentioned)
Prev. (prevalence): values indicate the highest observed prevalence (%) of the signs/symptoms or life impacts in the publications (−, not mentioned). Prevalence values of 50% or above are highlighted in bold
aPublications could report data for more than one subpopulation
bSigns/symptoms and life impacts mentioned in at least 25% of the publications for any subpopulation were included
ADL activities of daily living, CKD chronic kidney disease, freq. frequency, prev. prevalence, NR not reported